Integrates MRI, PET, cognitive testing, and biofluid biomarkers to characterize the trajectory of late-onset and autosomal-dominant Alzheimer's disease. Studies how APOE, amyloid, tau, neural-injury markers, and functional brain changes predict longitudinal cognition and disease progression.